Supernus Pharma Gets Tentative FDA Approval For Trokendi XR - Quick Facts

Trade SUPN now with

6/26/2012 8:12 AM ET

Supernus Pharmaceuticals, Inc. (SUPN: Quote) said it received a tentative approval letter from the FDA for Trokendi XR, a once-daily extended release formulation of topiramate.

The letter stated that the FDA completed its review of the Trokendi XR NDA and that no additional clinical trials are required. Supernus said its initial understanding is that final approval is conditioned on resolving a marketing exclusivity issue raised by the FDA regarding a specific pediatric population.

"We are pleased to announce that the FDA granted us tentative approval for Trokendi XR and that all of the scientific and procedural conditions for approval have been met. We will continue to work closely with the FDA to further understand the outstanding issue and move forward towards final approval," said Jack Khattar, Chief Executive Officer, President and Director of Supernus.

Click here to receive FREE breaking news email alerts for Supernus Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 40 Articles

Editors Pick

Upbeat Economic Data Contributes To Rally On Wall Street - U.S. Commentary

Stocks moved sharply higher over the course of the trading day on Friday, more than offsetting the weakness seen on Thursday. In a reversal from the previous session, the markets benefited from some upbeat U.S. economic data as well as comments from a Federal Reserve official. The major averages saw further upside going into the close, with the Dow and the S&P 500 reaching new record highs.

PETA: IRS Targeting Neither New Nor Limited To Conservative Causes

As the IRS targeting scandal continues to make headlines, animal-protection charity People for the Ethical Treatment of Animals, or PETA, claims that conservative groups are not the only ones that have faced increased scrutiny from the agency.

Polls Shows Below Average Interest In IRS, Benghazi Stories

While the IRS targeting scandal has taken center stage on Capitol Hill on Friday, the results of a new Gallup poll showed that the American public's interest in the story is comparatively low based on historical measures. The poll showed that 54 percent of Americans are following the news that the IRS targeted conservative groups for greater scrutiny "very" or "somewhat" closely.